Topas is an early stage therapeutics company, and utilizing its nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver.
Topas Therapeutics GmbH
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Topas unique platform is built on proprietary nanoparticles that selectively targets liver sinusoidal endothelial cells (LSECs) and deliver peptides to such cells. LSECs are one of the bodys premier sites to induce tolerance against blood borne antigens by generating peptide specific regulatory T cells; this natural pathway is utilize by Topas technology to develop drugs against autoimmune diseases, allergies and drug induced immune reactions where the antigen and its respective antigenic peptide is known.
In Apr 2018, Topas entered into a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance induction with an initial focus on virus-based delivery vectors that confer novel therapeutics to patients. Previously, in 2017, Boehringer had provided 5Mn USD to accelerate the preparation and execution of clinical trials for autoimmune programs derived from its platform.
In Mar 2016, Topas Therapeutics raised EUR 15 Mn in series A financing round. The round was led by Epidarex Capital and includes EMBL Ventures, Gimv and Evotec AG.